ERBB2 and triple-negative breast carcinoma: Hormone receptor positive (HR+) tumors which express ER and PR represent 60–70% of new cases, HER2+ tumors represent 10–20% of cases, while the remaining 15–20% of tumors are defined as triple negative breast cancers (TNBC) and lack expression of ER, PR and HER2.